Visual Screening for Malignant Melanoma

A Cost-effectiveness Analysis

Elena Losina, PhD; Rochelle P. Walensky, MD, MPH; Alan Geller, RN, MPH; Frederick C. Beddingfield III, MD, PhD; Lindsey L. Wolf, SB; Barbara A. Gilchrest, MD; Kenneth A. Freedberg, MD, MSc

Objective: To evaluate the cost-effectiveness of various melanoma screening strategies proposed in the United States.

Design: We developed a computer simulation Markov model to evaluate alternative melanoma screening strategies.

Participants: Hypothetical cohort of the general population and siblings of patients with melanoma.

Intervention: We considered the following 4 strategies: background screening only, and screening 1 time, every 2 years, and annually, all beginning at age 50 years. Prevalence, incidence, and mortality data were taken from the Surveillance, Epidemiology, and End Results Program. Sibling risk, recurrence rates, and treatment costs were taken from the literature.

Main Outcome Measures: Outcomes included life expectancy, quality-adjusted life expectancy, and lifetime costs. Cost-effectiveness ratios were in dollars per quality-adjusted life year ($/QALY) gained.

Results: In the general population, screening 1 time, every 2 years, and annually saved 1.6, 4.4, and 5.2 QALYs per 1000 persons screened, with incremental cost-effectiveness ratios of $10 100/QALY, $80 700/QALY, and $586 800/QALY, respectively. In siblings of patients with melanoma (relative risk, 2.24 compared with the general population), 1-time, every-2-years, and annual screenings saved 3.6, 9.8, and 11.4 QALYs per 1000 persons screened, with incremental cost-effectiveness ratios of $4000/QALY, $35 500/QALY, and $257 800/QALY, respectively. In higher risk siblings of patients with melanoma (relative risk, 5.56), screening was more cost-effective. Results were most sensitive to screening cost, melanoma progression rate, and specificity of visual screening.

Conclusions: One-time melanoma screening of the general population older than 50 years is very cost-effective compared with other cancer screening programs in the United States. Screening every 2 years in siblings of patients with melanoma is also cost-effective.

Arch Dermatol. 2007;143:21-28

MELANOMA IS THE ONLY cancer for which incidence and mortality rates are rising unabated, while screening, the potential means for reducing the burden of disease, continues to be underused.1 In contrast to other early detectable cancers, including breast, prostate, colorectal, and cervical cancers, with recently decreasing mortality rates, the mortality rate for melanoma in the United States increased by 29% from 1975 to 2000.1,2

CME course available at www.archdermatol.com

More than 62 000 new invasive melanoma cases are predicted for 2006, and the cost of treating melanoma exceeds $740 million annually in the United States.3–4 The prevalence and incidence of melanoma increase with age, particularly after age 50 years.1 Siblings of patients with melanoma are at increased risk of developing melanoma; the risk is at least double for first-degree relatives of patients with melanoma and is 5-fold higher if 2 first-degree relatives or more are affected.3

See also pages 30 and 101

Identifiable risk factors, increasing incidence, and the availability of curative treatment for early melanoma have stimulated interest in melanoma screening programs by dermatologists during a brief focused visit.6 In a 3-year follow-up of almost 250 000 persons in the United States attending free skin cancer screenings by der-
matologists, melanoma was diagnosed in 363 (1.5 cases per 1000 individuals screened).

The lack of evidence of screening efficacy from a randomized trial has been cited as an obstacle to population-based melanoma screening, yet the cost of such a trial seems prohibitive. Additional concerns about the expansion of screening include questions of test accuracy, the cost of screening, and lead-time bias.

To understand these obstacles to melanoma screening, we developed a simulation Markov model to examine the potential impact of melanoma screening by a dermatologist. Our objective was to evaluate the impact and cost-effectiveness of alternative melanoma screening programs in both the general population and a high-risk population including siblings of patients with melanoma.

### METHODS

#### MODEL OVERVIEW

We developed a computer simulation, state-transition Markov model to evaluate alternative strategies for melanoma screening compared with background screening alone. Disease progression, rates of recurrence, mortality, and costs of melanoma treatment depended on disease stage and lesion thickness (Table 1). The model differentiated between local disease (stages I and II), metastatic disease with local lymph node involvement (stage III), and distant metastases (stage IV). Local disease was further divided into 4 groups according to lesion size, as follows: less than 0.76 mm (stage IA), 0.76 to 1.50 mm (stage IB), 1.51 to 3.99 mm (stage IIA), and 4.00 mm or larger (stage IIB). Most data available on melanoma stage-specific incidence, prevalence, and survival were based on the 1992 American Joint Committee on Cancer staging system. To capitalize on the best data to support the model structure, we signed the model using this staging system.

The model consisted of the following 5 mutually exclusive health states: melanoma free, undiagnosed melanoma, newly diagnosed melanoma, history of melanoma, and death (Figure 1). Transitions from the melanoma-free to the undiagnosed melanoma state were governed by age-dependent prevalence and incidence. Incidence rates ranged from 28.7 per 100 000 persons at age 50 years to 55.9 per 100 000 persons at age 80 years; prevalence rates ranged from 0.196% at age 50 years to 0.292% at age 80 years. Patients who developed melanoma remained in the undiagnosed state until a dermatologist confirmed the diagnosis and initiated treatment. False-negative screening results may also be obtained in patients with melanoma; these patients remained in the undiagnosed state. While in the undiagnosed state, the model allowed disease progression. Transition from the undiagnosed to the newly diagnosed state was defined by either background screening or a prespecified screening frequency. Patients having been diagnosed with melanoma were treated and transitioned to the history of melanoma state, in which risk of melanoma recurrence was increased. Patients with melanoma, regardless of diagnostic status, had higher mortality according to disease stage than did patients who were melanoma free. Mortality in the melanoma-free population was governed by age- and gender-specific US life tables.

Outcomes from the model included projected life expectancy, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios. The analyses were performed from a health care system perspective (third-party payer), excluding patient and time costs, with 3% discounting of costs and life expectancy.

### CLINICAL DATA

We used data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute to derive age-specific incidence and prevalence of melanoma. We incorporated an increase in relative risk of melanoma in siblings of patients with melanoma of 2.24, and in those with multiple affected first-degree relatives of 5.56. Five-year survival ranged from 92% for stage I disease to 13% for stage IV disease and was derived from the Surveillance Epidemiology and End Results Program. Survival probabilities at 5 and 10 years were derived from a subset of data from this program (1988-1998) by one of us (F.C.B.). Accuracy of visual screening in the ab-

---

Table 1. Base Case Parameter Estimates for Melanoma Screening*

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Base Case</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-y Survival†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>0.92 (0.81-0.99)</td>
<td>10, 11</td>
</tr>
<tr>
<td>Stage 2</td>
<td>0.72 (0.65-0.79)</td>
<td>11</td>
</tr>
<tr>
<td>Stage 3</td>
<td>0.50 (0.45-0.55)</td>
<td>11</td>
</tr>
<tr>
<td>Stage 4</td>
<td>0.13 (0.11-0.15)</td>
<td>11</td>
</tr>
<tr>
<td>Increased risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>General population</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Siblings‡</td>
<td>2.24 (1.00-10.00)</td>
<td>5</td>
</tr>
<tr>
<td>Siblings at high risk§</td>
<td>5.56 (1.00-10.00)</td>
<td>5</td>
</tr>
<tr>
<td>Screening</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>85 (70-100); beta (19, 3)</td>
<td>12</td>
</tr>
<tr>
<td>Specificity, %</td>
<td>99 (70-100); beta (30, 1)</td>
<td>12</td>
</tr>
<tr>
<td>Cost, $</td>
<td>41 (21-123); normal (40, 15)</td>
<td>13, 14</td>
</tr>
<tr>
<td>Progression rate, %</td>
<td>10 (0-50); beta (0.3, 2.7)</td>
<td>1</td>
</tr>
<tr>
<td>Treatment costs, $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 1</td>
<td>1732 (1299-2165)</td>
<td>3</td>
</tr>
<tr>
<td>Stage 2</td>
<td>4361 (3271-5451)</td>
<td>3</td>
</tr>
<tr>
<td>Stage 3</td>
<td>55 080 (41 310-68 850)</td>
<td>3</td>
</tr>
<tr>
<td>Stage 4</td>
<td>56 059 (42 044-70 074)</td>
<td>3</td>
</tr>
<tr>
<td>Health state utilities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stages 1 and 2</td>
<td>0.937</td>
<td>15</td>
</tr>
<tr>
<td>Stages 3 and 4</td>
<td>0.52</td>
<td>15</td>
</tr>
</tbody>
</table>

*Values in parentheses are given as range used in sensitivity analysis; distribution used for probabilistic sensitivity analysis. All costs are reported in 2004 US dollars.
†Based on the 1992 American Joint Committee on Cancer staging system.
‡Those with 2 or more first-degree relatives having been diagnosed with melanoma.
§Those with 1 first-degree relative having been diagnosed with melanoma.
||Assumption based on expert opinion, varied in sensitivity analysis.

---

Figure 1. Model structure. See “Methods” section for details.
sence of a biopsy specimen was obtained from the Skin and Cancer Unit of New York University Medical Center, New York City, and included 85% sensitivity and 99% specificity. When visual inspection and biopsy results differed, the biopsy results were used in decision making. In patients in the undiagnosed melanoma state, we assumed a progression rate from one stage or thickness to the next of 10% per year. After discussion with experts, we used this estimate in the base case to ensure a conservative analysis. We applied age-adjusted quality-of-life weights to melanoma survival, incidence, prevalence, progression rates, in-domicence (higher incremental cost-effectiveness ratios compared with more effective strategies). Outcomes for each strategy are expressed in years of life saved and in quality-adjusted life years (QALY). These outcomes enabled comparison of the cost-effectiveness of melanoma screening with other health care interventions.

POPULATIONS CONSIDERED

We considered 3 populations: a general population, siblings of patients with melanoma (1 first-degree relative having been diagnosed as having melanoma, hereafter called siblings), and higher risk siblings of patients with melanoma (at least 2 first-degree relatives having been diagnosed as having melanoma, hereafter called siblings at high risk). The 2 populations of siblings of patients with melanoma differ from each other and from the general population with respect to an increased risk of melanoma applied to both prevalence and incidence (Table 1).

BASE-CASE ANALYSIS: GENERAL POPULATION

In the general population, no screening was associated with a projected discounted quality-adjusted life expectancy, from age 50 years, of 13.537 QALYs, with lifetime skin cancer and screening-related costs of $236 per person. These costs are from occasional referrals to a dermatologist and comprise all direct costs associated with these referrals. One-time, every-2-years, and annual screening increased projected life expectancy to 13.539, 13.542, and 13.543 QALYs, respectively, saving 1.6, 4.4, and 5.2 QALYs, respectively, per 1000 persons screened. The incremental cost-effectiveness ratios were $10 100/QALY gained ($7400 per unadjusted year of life saved [YLS]) for 1-time screening at age 50 years compared with no screening, $80 700/QALY gained ($54 700/YLS) for every-2-years screening compared with 1-time screening, and $586 800/QALY gained ($398 600/YLS) for annual screening compared with every-2-years screening (Table 2).

### Table 2. Cost-effectiveness of Screening for Melanoma in the General Population and in Siblings of Patients With Melanoma

<table>
<thead>
<tr>
<th>Screening Frequency</th>
<th>General population</th>
<th>Siblings of patients with melanoma</th>
<th>Higher risk siblings of patients with melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>No screening program</td>
<td>236</td>
<td>316</td>
<td>537</td>
</tr>
<tr>
<td>1 Time, at age 50 y</td>
<td>252</td>
<td>331</td>
<td>545</td>
</tr>
<tr>
<td>Every 2 years beginning at age 50 y</td>
<td>481</td>
<td>550</td>
<td>753</td>
</tr>
<tr>
<td>Every year beginning at age 50 y</td>
<td>905</td>
<td>970</td>
<td>1162</td>
</tr>
</tbody>
</table>

**Abbreviations:** QALY, quality-adjusted life year; ellipses, an incremental cost-effectiveness ratio cannot be calculated for the baseline strategy.

*All costs are reported in 2004 US dollars.

COSTS

The model included direct medical costs related to melanoma treatment. Treatment costs, which ranged from $1732 for stage I disease to $56 059 for stage IV disease, were obtained from published literature. We assumed costs as follows: screening, $41; biopsy, $245; follow-up visit, $109; and pathologic analysis, $68. All costs were updated to 2004 US dollars using the medical care component of the Consumer Price Index.

SCREENING STRATEGIES

We considered the following 4 screening strategies: background screening only; that is, skin examination at a routine nondermatologist physician visit, followed by referral to a dermatologist, on average, once every 5 years; and 1-time, every-2-years, and annual screening by a dermatologist, all beginning at age 50 years. We compared outcomes from the more frequent to less frequent screening strategies using incremental cost-effectiveness ratios. The incremental cost-effectiveness ratio for a strategy (the added cost divided by the added life expectancy) was calculated in comparison with the next most effective strategy after eliminating dominated strategies (more costly and less effective) and strategies with extended dominance (higher incremental cost-effectiveness ratios compared with more effective strategies). Outcomes for each strategy are expressed in years of life saved and in quality-adjusted life years (QALY). These outcomes enabled comparison of the cost-effectiveness of melanoma screening with other health care interventions.

### RESULTS

In the general population, no screening was associated with a projected discounted quality-adjusted life expectancy, from age 50 years, of 13.537 QALYs, with lifetime skin cancer and screening-related costs of $236 per person. These costs are from occasional referrals to a dermatologist and comprise all direct costs associated with these referrals. One-time, every-2-years, and annual screening increased projected life expectancy to 13.539, 13.542, and 13.543 QALYs, respectively, saving 1.6, 4.4, and 5.2 QALYs, respectively, per 1000 persons screened. The incremental cost-effectiveness ratios were $10 100/QALY gained ($7400 per unadjusted year of life saved [YLS]) for 1-time screening at age 50 years compared with no screening, $80 700/QALY gained ($54 700/YLS) for every-2-years screening compared with 1-time screening, and $586 800/QALY gained ($398 600/YLS) for annual screening compared with every-2-years screening (Table 2).
In sensitivity analyses, we varied model parameters across a wide range (Table 1). We found that screening cost, melanoma progression rate, and specificity for melanoma detection by visual screening were the 3 most important parameters in the analysis (Figure 2). When we varied the cost of the visual screening from $21 (half of the $41 base case) to $123 (3 times the base case), the cost-effectiveness ratios for 1-time screening in both the general population and siblings of patients with melanoma remained less than $50 000/QALY gained. The cost-effectiveness ratio for screening siblings every 2 years remained less than $100 000/QALY gained the screening cost was no more than 2½ times the base case value (Figure 2A).

As the annual progression rate of melanoma decreased, screening every 2 years became less cost-effective (Figure 2B). At a progression rate of 5% per year, screening every 2 years of the general population cost $120 600/QALY gained compared with screening 1 time. When the progression rate dropped to less than 7% per year, the incremental cost-effectiveness ratio for screening every 2 years for siblings increased to more than $50 000/QALY gained compared with screening 1 time. For siblings at high risk, when the progression rate dropped to less than 2% per year, the incremental cost-effectiveness ratio increased to more than $50 000/QALY gained compared with 1-time screening. We also examined higher progression rates (data not shown in figure). For the general population, when progression rates exceeded 36% per year, the less frequent screening strategies (no screening and 1-time screening) were dominated by screening every 2 years and annually. For siblings, the incremental cost-effectiveness ratio comparing screening annually with every 2 years was $224 600/QALY gained at a 36% progression rate. To further examine the sensitivity of the results to assumptions about the progression rate, we assumed no progression of undiagnosed melanoma in lesions less than 0.76 mm thick. This changed the results of the analysis minimally, increasing the cost-effectiveness ratio of 1-time screening in the general population by 6% and of screening every 2 years in siblings of patients with melanoma by 10%. When we doubled the progression rate of undiagnosed melanoma in lesions less than 0.76 mm thick to 20%, the cost-effectiveness ratios of 1-time screening in the general population and screening every 2 years in siblings of patients with melanoma decreased by 4% and 7%, respectively.

We also varied the specificity for melanoma detection by visual screening from 100% to 70% (Figure 2C). As specificity decreased, the cost-effectiveness ratio for 1-time screening compared with no screening in the general population remained less than $50 000/QALY gained, increasing from $9200/QALY gained at 100% specificity to $44 500/QALY gained at 70% specificity. For siblings, the incremental cost-effectiveness of screening every 2 years compared with 1-time screening remained less than $100 000/QALY gained at specificity values of 80% and greater, with the cost-effectiveness ratio ranging from $32 500/QALY gained at 100% specificity to $137 000/QALY gained at 70% specificity. The sensitivity of melanoma detection by visual screening had little effect on the results. The cost-effectiveness ratio for 1-time screening in the general population ranged from $93 000/QALY gained to $11 100/QALY gained for sensitivity values of 100% and 70%, respectively. The incremental cost-
effective for screening every 2 years compared with 1-time screening in siblings was less than $50 000/QALY gained when sensitivity was greater than 72%. At a sensitivity of 70%, the incremental cost-effectiveness ratio for screening every 2 years compared with 1-time screening in siblings was $53 400/QALY gained. Results were not sensitive to changes in survival by stage, incidence and prevalence of disease, discount rate, costs of care, and quality-of-life estimates.

SENSITIVITY OF RESULTS TO POTENTIAL LEAD-TIME BIAS AND LENGTH BIAS

To examine the effect of potential lead-time bias on the results (the screened group of siblings had the potential to be diagnosed earlier), we assumed that less frequent screening would be used in patients with slower progressing disease (progression rate of 7%, a 30% reduction from the base case). The corresponding incremental cost-effectiveness ratios were, respectively, $24 500/QALY gained, $49 200/QALY gained, and $260 900/QALY gained for screening 1 time, every 2 years, and annually. From a policy perspective, these results are similar to the base case results.

To assess the effect of length bias on the results (faster progressing disease will be identified less often by screening), we considered a hypothetical population of siblings with fast progressing disease (progression rate of 15%, a 50% increase from the base case). In this population, the quality-adjusted life expectancies were, respectively, 13.526, 13.530, 13.539, and 13.540 QALYs per person for no screening and for screening 1 time, every 2 years, and annually. The cost-effectiveness ratios were $2400/QALY gained, $18 600/QALY gained, and $253 300/QALY gained for screening 1 time, every 2 years, and annually.

PROBABILISTIC SENSITIVITY ANALYSIS

To further examine the sensitivity of our results to variation in imperfect model parameters, we also performed a probabilistic sensitivity analysis, drawing values from distributions for screening cost, sensitivity, specificity, and melanoma progression rate (Table 1). Comparing screening every 2 years with screening 1 time in siblings, the probability that the incremental cost-effectiveness ratio was less than a threshold of $100 000/QALY gained was 0.77 and the probability that it was less than $50 000/QALY gained was 0.42 (Figure 3). These results suggest that if decision makers are willing to pay $100 000 or $50 000 for each additional QALY gained, screening siblings every 2 years will be cost-effective compared with 1-time screening 77% or 42% of the time, respectively.

We developed a state-transition model to assess melanoma disease progression with time and used it to estimate the impact and value of various melanoma screening programs. We found that 1-time melanoma screening by dermatologists in the US general population at age 50 years and screening of siblings of patients with melanoma every 2 years have cost-effectiveness ratios of $10 100/QALY gained and $35 500/QALY gained, respectively. These ratios are comparable to those for other types of cancer screening, including breast, cervical, and colorectal cancers, all of which are recommended by the US Preventive Services Task Force (Table 3). If screening costs could be reduced below the base case estimate of $41 per screening, screening would be even more cost-effective.

Cost-effectiveness analysis is particularly useful when randomized controlled trials cannot be done because of ethical or logistic considerations. In the case of melanoma, the low overall disease prevalence and incidence would require more than 360 000 study participants followed up for 10 years to identify statistically significant differences in the outcome of screening. Cost-effectiveness analysis is most often used when decisions are being made in the absence of randomized trials with mortality end points and when the best available data can be combined from numerous sources to inform policy. Such analyses have been used to guide clinical decision making in colon cancer screening, breast cancer screening, and human immunodeficiency virus disease management, among others. Using this method, interventions in the United States are generally considered cost-effective at less than $50 000/QALY gained or less than $100 000/QALY gained.
Several previous studies have estimated the cost-effectiveness of melanoma screening. Freedberg et al. estimated a cost-effectiveness ratio of $39 600/YLS for 1-time screening in a population at high risk. That study was limited to 1-time screening, which was applied in a younger age group. The current study estimated a cost-effectiveness ratio of $220 700/YLS for 1-time screening in a population at high risk. The USPSTF found at least fair evidence that melanoma screening improves health outcomes and concludes that benefits outweigh harm. The USPSTF concluded that the evidence is insufficient to recommend for or against routine melanoma screening.

To our knowledge, there are no trials of melanoma screening in the United States. Given the high prevalence of this disease, the USPSTF believed that melanoma screening was cost-effective in a younger age group. The cost-effectiveness for older patients was much lower, at $28 700/YLS. While this estimate differs from that in the current analysis, owing to differences in defining the higher risk population and screening cost, the policy recommendations are similar. Other cost-effectiveness analyses of melanoma prevention strategies have been done in Australia and Italy. The Australian study, by Girgis et al., found the cost-effectiveness of screening every 2 years for melanoma by family practice physicians (60% sensitivity) to be $15 000/YLS for men aged 50 years and $25 800/YLS for women aged 50 years. While these results are similar to those in the current study, this is likely owing to both the increased prevalence and incidence of melanoma in Australia compared with the United States and the lower sensitivity of screening by family practice physicians in their study. Cristofolini et al., in Italy, evaluated the cost-effectiveness of an educational campaign for early diagnosis of melanoma and did not address screening strategies.

To our knowledge, there are no trials of melanoma screening in the United States, and melanoma screening was not included as part of the National Cancer Institute Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Without conclusive evidence, committees have had to rely on observational evidence that suggests but does not prove the effectiveness of melanoma screening in the detection of thinner melanomas, the main determinant of prognosis.

This study has several limitations. Although they represent the best available published data, these data were derived from multiple sources. Lead-time and length bias may have a role in survival benefit from earlier diagnosis of melanoma, although sensitivity analyses suggest that these have modest effects on the general policy conclusions of this analysis. The actual rate of melanoma progression is unknown; while this had little effect on 1-time screening, the results of screening every 2 years were sensitive to the progression rate. Although in the base-case analysis our model assumed a constant progression rate of 10% from one stage to another, results of the sensitivity analysis confirmed that varying the progression rate between stages did not affect the conclusions. Because the progression rate for any malignancy is unknown, researchers must make specific assumptions about progression rates to examine the cost-effectiveness of screening strategies. Assumptions similar to ours were used in analyses of the cost-effectiveness of screening for breast and colon cancers. The comprehensive set of sensitivity analyses varying progression rate in this article provides important insight into the role of the progression rate in assessment of the cost-effectiveness of screening for malignant melanoma (Figure 2B).

Recent evidence also suggests that patients with a family history of melanoma are at increased risk for second primary melanomas. While not explicitly modeled in this analysis, to the extent that second primary cases represent a major problem and that the incidence of a second primary melanoma in a patient with melanoma is higher than the incidence of a first primary melanoma in otherwise similar patients, screening programs will be even
more cost-effective.42-43 While costs of false-positive results are included in this analysis, quality-of-life decrements are not. Given that false-positive results are observed in only about 1% of persons screened and that a false-positive result provides only a small decrement in overall quality of life, the effect of false-positive results on the quality-adjusted life expectancy of the cohort is minimal. Finally, the model did not account for the detection of nonmelanoma skin cancer, which is approximately 20 times more common than melanoma and shares many of the same risk factors.44 Nonmelanoma skin cancer may be diagnosed in a melanoma screening program, adding both costs and benefits. Because the benefits from detection of these lesions are uncertain and there are insufficient data to quantify them, they were not included. Furthermore, the study by Beddingfield,45 which included costs of nonmelanoma skin cancer, reported that, while the cost-effectiveness ratio increased by about 23% ($16,900/YLS), the policy recommendations did not change.

The improvements in life expectancy suggested by the results of this study were moderate because only those individuals who develop melanoma gain a survival benefit from screening. Since the prevalence of melanoma in the United States is low, mean life expectancy improvements across the population were limited. In general, increases in life expectancy as a result of screening are smaller than increases as a result of treatment because all patients receiving treatment have the disease.45

What is the future of melanoma screening? The Institute of Medicine did not endorse screening because of lack of efficacy data, yet there is no ongoing effort to obtain such data in the United States. This study suggests that 1-time screening of the general US population at age 50 years for malignant melanoma is very cost-effective and that screening every 2 years of siblings of patients with melanoma may also be cost-effective, depending on disease progression rates. Either screening programs should be expanded or efforts to perform a definitive efficacy trial should be initiated.

Accepted for Publication: May 4, 2006.
Correspondence: Elena Losina, PhD, Department of Biostatistics, Boston University School of Public Health, 715 Albany St, Boston, MA 02118 (elosina@partners.org).

Author Contributions: Study concept and design: Losina, Walensky, Gilchrest, and Freedberg. Acquisition of data: Losina, Geller, and Beddingfield. Analysis and interpretation of data: Losina, Walensky, Beddingfield, Wolf, Gilchrest, and Freedberg. Drafting of the manuscript: Losina, Geller, and Wolf. Critical revision of the manuscript for important intellectual content: Losina, Walensky, Beddingfield, Wolf, Gilchrest, and Freedberg. Statistical analysis: Losina. Obtained funding: Losina, Geller, and Freedberg. Administrative, technical, and material support: Losina, Beddingfield, Wolf, Gilchrest, and Freedberg. Study supervision: Losina and Freedberg. Framing issues: Gilchrest.

Financial Disclosure: None reported.

Funding/Support: This study was supported by grant R01CA76333 from the National Cancer Institute and grants K25AI50436, K23AI07194, and K24AI062476 from the National Institute of Allergy and Infectious Diseases.

REFERENCES

33. Hirth RA, Ubel PA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.